Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting - Seite 2

Comparison of Two Different MIGS Devices with Combined Canaloplasty in Moderate Glaucoma at the Time of Cataract Surgery

• Deborah Ristvedt, DO
  Third-Generation Trabecular Micro-Bypass in Eyes Failing Prior Surgical and/or Medical Glaucoma Therapy

• Valerie Trubnik, MD
  Usage of Three Trabecular Mico-Bypass Stents Combined with Phacoemulsification in Surgically Naïve Glaucoma Patients

• Zachary Vest, MD
  Early Outcomes After Third-Generation Trabecular Micro-Bypass Performed with Phacoemulsification in Patients with Open-Angle Glaucoma

• Edward Yung, MD
  Outcomes after Viscoelastic Delivery in Patients with Glaucoma

Key Corneal Health Presentations:
Friday, April 5, 2024

• 9:13-9:21 a.m., Michael Raizman, MD
  Cross-Linking – Now and What’s Coming

Saturday, April 6, 2024

• 3:31-3:41 p.m., Brandon Ayres, MD
  Keratoconus – Surgical Innovations

Sunday, April 7, 2024

• 10:00-10:05 a.m., Kenneth Beckman, MD
  Safety of a Scanning Laser-based Bioactivation System for Corneal Cross-Linking in Keratoconus

Abstract information can be found at https://annualmeeting.ascrs.org.

The ASCRS Annual Meeting is among the largest gatherings of anterior segment physicians, medical personnel and industry executives in the ophthalmic industry. All educational content of the ASCRS Annual Meeting is planned by its program committee, and ASCRS does not endorse, promote, approve or recommend the use of any products, devices or services.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.